CD206+ TAMs function as cross‐presenting cells and strongly express CD86, inducible T‐cell costimulator ligand (ICOSLG), and C‐type lectin receptor 4A (CLEC4A), promoting antigen cross‐presentation and antigen‐specific CD8+ T‐cell activation, thereby reducing tumor burden [98]. Here, CD8A is linked to neoplasm.